Navigation Links
Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027
Date:10/25/2011

SAN DIEGO, Oct. 25, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the termination of its Phase 2 clinical trial of CTS-1027 in HCV patients.  This decision follows reports of laboratory abnormalities and adverse events in a subset of clinical trial participants.

The top priority of Conatus is patient safety, and the Company has made the decision to halt this study.  Conatus is conducting a thorough review of the available data to assess any future development of the compound.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics in the areas of fibrotic disease and oncology. Conatus' lead drug candidate, emricasan (IDN-6556) is in development as a potential therapy for a variety of fibrotic diseases. Fibrotic diseases affect millions of people worldwide and can be caused by many different types of injuries. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer.  Conatus acquired the Idun subsidiary from Pfizer in 2010.  For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oramed Pharmaceuticals Chosen to Present at the Diabetes Technology Meeting (October 27-29, 2011; San Francisco, CA)
2. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
3. Syndax Pharmaceuticals to Present at Upcoming Fall Conferences
4. Avanir Pharmaceuticals to Present Data at MS-Focused ECTRIMS Annual Meeting
5. Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
6. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
7. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
8. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
9. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
10. Anadys Pharmaceuticals Updates Its Presentation Date at the Stifel Nicolaus Healthcare Conference
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Leading CEOs from biotech, pharmaceutical, ... and June 1st at The Four Seasons Hotel Boston. , The Boston CEO ... offering exclusive access to key decision makers who influence deal making and investment. ...
(Date:5/3/2016)... - And Other Rising Companies ... Those Competitor Biologics  - Biosimilar Drug Producers ... ,  Who are the most important and ... their sales potentials? Discover, in our updated survey, organisations, ... and revenue forecasting. Visiongain,s new ...
(Date:5/2/2016)... , May 2, 2016 Q ... its technology partner Mannin Research Inc. will be attending ... which takes place from May 1-5, 2016 in ... be meeting with its vendors and research partners. The ... development goals and other collaborative opportunities for the MAN-01 ...
(Date:4/29/2016)... ... ... The MIT bioLogic design team has won multiple A' Design Awards ... applied to fabric and formed into living interfaces between body and environment. They found ... team harvested Natto cells and applied them to fabric with custom 3D printers.The cell-infused ...
Breaking Biology Technology:
(Date:3/10/2016)... -- --> --> ... Access Management Market by Component (Provisioning, Directory Services, Password ... Size, by Deployment, by Vertical, and by Region - ... is estimated to grow from USD 7.20 Billion in ... Compound Annual Growth Rate (CAGR) of 12.2% during the ...
(Date:3/8/2016)... 8, 2016   Valencell , the leading ... it has secured $11M in Series D financing. ... new venture fund being launched by UAE-based financial ... existing investors TDF Ventures and WSJ Joshua Fund. ... its triple-digit growth and accelerate its pioneering innovation ...
(Date:3/2/2016)... 2016 http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) ... "Global Biometrics as a Service Market 2016-2020" ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced the ... a Service Market 2016-2020" report to ... and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced ...
Breaking Biology News(10 mins):